Rani Therapeutics Holdings Inc（RANI）財務資料RANIRani Therapeutics Holdings Inc

Evaluating the bottom line, Rani Therapeutics Holdings Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -516.86%, while the net margin is -493.03%. These profitability ratios, combined with a Return on Equity (ROE) of -179.10%, provide a clear picture of how effectively RANI converts its operational activities into shareholder value.

In the context of the broader market, RANI competes directly with industry leaders such as RLYB and COYA. With a market capitalization of $75.51M, it holds a significant position in the sector. When comparing efficiency, RANI's gross margin of 100.00% stands against RLYB's N/A and COYA's 100.00%. Such benchmarking helps identify whether Rani Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

Rani Therapeutics has shown a gross margin of 100% in recent quarters, but the company continues to report substantial net losses, with a net income of -$8.4 million for Q2 2026. The current ratio has improved to 5.31, indicating better liquidity, but the overall financial outlook remains challenging with a debt-to-equity ratio of 0% and a price-to-sales ratio of 14.87, suggesting the stock may be overvalued relative to its revenue.